Comparative Pharmacology
Head-to-head clinical analysis: STATROL versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STATROL versus TRIESENCE.
STATROL vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
10 mg orally once daily
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category C
Category C
Otic Antibiotic/Corticosteroid
Corticosteroid